In the EU, rare diseases that are also life-threatening or chronically debilitating with a low prevalence and a high level of complexity are defined as orphan diseases.
Personalized medicines are an exciting new area that is becoming possible because we can now iden
Health Technology Assessment (or HTA) is the ‘multi-disciplinary field of policy analysis, which
EuropaBio is a founding member of the EPAA – the European Platform for Alternative Approaches to
The purpose of HTA is to provide high-quality information to decision makers about the clinical e
Biological medicines are far more complex and usually much bigger than chemical medicines, which